Published on April 25, 2016
[Editor’s note: On January 4, 2020 Bob Azopardi, after fighting CLL for many years, passed away in his sleep at his home on Long Island, New York. Bob had several low times with CLL before but also received great benefit from being in a clinical trial for the medicine that became venetoclax (Venclexta). Bob entered that trial when his wife urged him to consult with a physician researcher. Given the benefit he received, Bob spoke out many times to patients and researchers, on videos, at events, and even in a huge stadium to express his gratitude and wish for other patients to get expert care. Patient Power is thankful Bob was with us so many times. We will miss him, but his message continues.]
Patient Power Founder, Andrew Schorr, interviewed Bob Azopardi, a 16-year CLL patient who participated in the Phase III arm of the venetoclax (Venclexta) clinical trial. Bob discusses his involvement on the trial including the many safety precautions in place for patients and the new quality of life he experiences.